Repare Therapeutics

RPTX

Biotech

Pharma

Country

CA

Industry

Health Care

Market Cap

Small Cap

Num. Employees

180

IPO Date

Jun 19, 2020

Create Alert

RPTX

Country

CA

Industry

Health Care

Biotech

Pharma

Create Alert

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company is headquartered in St-Laurent, Quebec and currently employs 180 full-time employees. The company went IPO on 2020-06-19. The firm uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop targeted cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. Using its SNIPRx platform, the Company is developing its pipeline of SL product candidates, including its lead product candidate, RP-3500, a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. The Company’s product pipelines include Camonsertib ATR Inhibitor, RP-6306 PKMYT1 Inhibitor and RP-2119 Pol Inhibitor. Its RP-6306 is being developed as a highly potent and selective PKMYT1 inhibitor that preferentially kills tumor cells overexpressing CCNE1.